Gamma Light and Sound Stimulation to Prevent Dementia in Cognitively Normal People at Risk for Alzheimer's Disease
NCT05776641
This study is recruiting at 2 US sites in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
Alzheimer's disease (AD) is characterized by significant memory loss, toxic protein deposits (amyloid and tau) in the brain, and changes in the gamma frequency band on EEG. Gamma waves are important for memory, and in patients with AD, there are fewer gamma waves in the brain. The Tsai lab found that boosting gamma waves in AD mouse models using light and sound stimulation at 40Hz not only reduced amyloid and tau in the brain, but also improved memory. A light and sound device was developed for humans that stimulates the brain at 40Hz that can be used safely at home.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Alzheimer Disease
- Family Members
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Not applicable
- Ages
- 55 to 90 years
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- Massachusetts General Hospital
- Last updated on ClinicalTrials.gov
- June 18, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Massachusetts · 2
- Massachusetts General Hospital · Boston, MA
- Massachusetts Institute of Technology · Cambridge, MA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.